# Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT03204812** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT03204812
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-14
- **Primary completion:** 2021-04-13
- **Final completion:** 2021-04-13
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204812, "Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03204812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*